Idelalisib and Y-90 Zevalin

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Idelalisib may cause serious and life-threatening diarrhea, and using it with other medications that also commonly cause diarrhea such as ibritumomab tiuxetan may increase that risk. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Call your doctor immediately if the number of bowel movements per day increases by six or more, or if you experience new or worsening abdominal pain, chills, fever, nausea, or vomiting. You may need a dose adjustment or an interruption in idelalisib therapy if you develop severe diarrhea. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea. In premarketing trials, serious and fatal diarrhea or colitis (Grade 3 or higher) occurred in 14% of patients receiving idelalisib. Diarrhea may occur at any time and responds poorly to antimotility agents. The median time to resolution across trials ranged from one week to one month following interruption of idelalisib therapy and, in some instances, use of corticosteroids. Serious and fatal intestinal perforation has also been reported with idelalisib. At the time of perforation, some patients had moderate to severe diarrhea.

MANAGEMENT: Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation. Patients should be advised to contact their physician immediately if the number of bowel movements per day increases by six or more, and to promptly report any new or worsening abdominal pain, chills, fever, nausea, or vomiting.

Idelalisib

Generic Name: idelalisib

Brand name: Zydelig

Synonyms: n.a.

What is Idelalisib?

Y-90 Zevalin

Generic Name: ibritumomab

Brand name: Y-90 Zevalin, In-111 Zevalin

Synonyms: n.a.

What is Y-90 Zevalin?